-
Crisaborole
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Crisaborole Atopic Dermatitis Ati Àléfọ Pfizer -
Etelcacetide
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Etelcacetide Atẹle hyperparathyroidism (HPT) Amgen -
Abemaciclib
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Abemaciclib Arun igbaya, itọju akàn pirositeti Eli Lily Oṣu kejila 15,2029 -
Deucracitinib
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Deucracitinib Anti plaque psoriasis Bristol-Myers Squibb Company Oṣu kọkanla 07, 2033 -
Apremilast
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Apremilast psoriatic arthritis Celgene -
Remdesivir
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Remdesivir Awọn ọlọjẹ (Ebola, Covid-19) Gileadi -
Paxlovid
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Paxlovid Covid 19 Pfizer -
Pomalidomide
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Pomalidomide Oogun Onkoloji Celgene -
Nirmatrelvir
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Nirmatrelvir 3C-Bi Protease (3CLPRO) inhibitor Ati SARS-Cov-2 Mpro inhibitor -
Eltrombopag
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Eltrombopag ITP & Aplastic ẹjẹ Novartis & GSK May. Ọdun 20, Ọdun 2023 -
Ruxolitinib
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Ruxolitinib Myelofibrosis Novartis Oṣu Keje Ọjọ 6, Ọdun 2024 -
Crisaborole
Orukọ API Itọkasi Innovator Ọjọ Itọsi Itọsi (AMẸRIKA) Crisaborole Atopic Dermatitis ati Àléfọ Pfizer Oṣu Kẹfa Ọjọ 11, Ọdun 2026